Date: 27 November, 2024

To, To,
The Manager The Manager
Listing Department Listing Department
National Stock Exchange (NSE) Bombay Stock Exchange (BSE)
Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers
Plot No. C/1, G-Block Dalal Street Mumbai - 400 001
Bandra-Kurla Complex Scrip Code:544282
Bandra (E), Mumbai - 400 051
Symbol: SAGILITY

Dear Sir/Ma’am,

Subject: Submission of Investor Presentation to be made to investors on November 27, 2024,

pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015

In continuation to our letter dated November 22, 2024, we are enclosing herewith the presentation to be
made to Investors on the Financial Results of Sagility India Limited for the quarter and half-year ended
September 30, 2024 scheduled on Wednesday, 27th November 2024 at 4:00PM (IST).

The details are also being made available on the Company’s website www.sagilityhealth.com

This is for your kind information and record.

Thanking You,

For Sagility India Limited

SATISHKUMAR Digitally signed by SATISHKUMAR
SAKHARAYAPATTANA
SAKHARAYAPATTANA SEETHARAMAIAH
SEETHARAMAIAH Date: 2024.11.27 12:31:51 +05'30'
Satishkumar Sakharayapattana Seetharamaiah
Company Secretary & Compliance Officer
Membership No: A16008

Encl: a/a

Sagility India Limited

(Formerly Sagility India Private Limited; earlier Berkmeer India Private Limited)
Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road,
Bommanahalli, Bengaluru – 560068 Karnataka India
Corporate Identity Number: U72900KA2021PLC150054
Tel. No.: 080-71251500, Website: www.SagilityHealth.com
Nov 27, 2024

Investor Deck – Q2 FY25

Safe Harbour

Certain statements in this release concerning Sagility’ future growth prospects may be seen as forward-
looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ
materially from such statements. Sagility does not undertake to update any such statement that may have
been made from time to time by or on behalf of the company..

2
We are one of the largest pure-play Healthcare Services and
Solutions provider
Broad and deep domain expertise Service Portfolio Tech-led & Transformative
in medical, pharmacy, and dental Insurance business Covers payer and provider value chain inclusive of Applications, point solutions, RPA, Analytics and AI
segments both administrative and clinical workflows

5 3 4 17
45 Of The Top 10 Payers Of top 6 PBMs by claims
Large national IDN,
Average tenure in years of
Healthcare Clients Groups Laboratory, DME and
Served volume Top 5 clients
Radiology Provider clients

Diverse and Broad Multi-shore, scalable

100% 24 client portfolio
Marquee Provider
and flexible delivery
Tenured Leadership &
Years of experience in clients powering Board with Healthcare
US Healthcare focused Payers, PBMs, TPAs, platform showcasing
Healthcare expansion strong certifications Expertise
Workers Comp

Revenue in Million
24.64% 12.40% 105M ~ 94%
38000+ 5 87.2%
~ 2000 Geographies 12.7%
Adjusted Adjusted
OCF to EBITDA
Claims processed
Headcount
Employees EBITDA Margin PAT Margin 75M+ Offshore &
Clinicians (32 Sites) (FY24)
(60% women) (FY24) (FY24) Interactions Nearshore

Supported by Talented workforce with expertise in claims, clinical and coding across multiple geographies
► Leader in Healthcare Payer Operations PEAK ► Leader in GenAI Service
Matrix - 2023 ► Leader in Clinical Services
Business Process Provider - 2024
► Major Contender in Clinical and Care Mgmt. Ops Transformation - 2023
Services & RCM Ops PEAK Matrix - 2023

► Best HR Strategy In ► Recognized by ► ‘Employer of

► Best Employer for ► Employer of the Year
Line With Business, LinkedIn as 15 best Choice’ award
Women, Ind Bronze Stevie(R)
World HRD Congress workplaces to grow a (JAM)
Economic Times Award (US) 3
IND career in PHL
 US Healthcare spending is highest among the leading economies
and is expected to continue increasing
US Healthcare Expenditure to reach 18.2% US is the Highest Healthcare Spender US Healthcare Outsourcing Potential
of US GDP by 2028 among Leading Economies

Health expenditure as % of US GDP at current prices Healthcare expenditure per capita vs. GDP per capita Payers form 68.7% & Providers form 31.3% of the overall TAM
(2022)2 (CY23)
US GDP at Current Prices ($tn)
Healthcare Expenditure as % of US GDP CY23
33.6

32.3 Overall Outsourcing Outsourcing

TAM ($) Penetration (%) Penetration ($)
31.0

29.8
28.8

Payer
27.4 17.9% 18.2% $138.2bn 22.0-24.0% ~$32bn+3
of $138.2bn
17.6%
17.0%
17.4%
17.1%

2023A 2024F 2025F 2026F 2027F 2028F

Provider
$62.9bn 19.5-21.5% ~$13bn4
▪ Healthcare forms an integral segment of the US economy, of $62.9bn
▪ US economy is the highest healthcare spender among
contributing 17.1% to the nominal GDP at $4.7tn spend in 2023 leading economies with per capita healthcare
expenditure (PPP Basis) at $12,555.3 in CY22
• +1.6x to the second-highest spender, Switzerland
• India’s healthcare market, in comparison, is underdeveloped
with 2021 estimates for health
$201.1bn ~$45.0bn

Total
spending per capita at $74.0

US Healthcare Outsourcing market growth is faster than the overall market driven by multiple tailwinds
Source: Industry research, OECD, IMF, WHO, CMS.
Note: 1. Currency conversion is based on the exchange rate of US$1 = INR 83.4982 as of 16th April 2024. 2. Current prices and PPP converted.
3.Calculated by multiplying outsourcing payer penetration average rate (%) of 22.0-24.0% to overall payer TAM ($) of $138.2bn for CY23. 4
4.Calculated by multiplying outsourcing provider penetration average rate (%) of 19.5-21.5% to overall provider TAM ($) of $62.9bn for CY23
Sagility exhibits end-to-end coverage across Payer and Provider
space…
Claims Payment Clinical Revenue Cycle
Management Integrity Management Others Management

Chronic & Complex Case

Intake, Indexing and Imaging Pre-Pay Enrolment Patient Engagement Services
Management

Adjudication Post-Pay Utilization Management Plan Building Claims and Coding Services

Population Health
Post Adjudication Premium Billing Revenue Management
Management

Provider Data Management &

Grievance & Appeals Clinical and Coding Denials
Credentialing

Patient Care, Quality &

Outcome Services

DME* & Lab Provider Order

Specialty Services

Member Engagement & Provider Engagement

Payer: Provider:
89.2% revenues1 10.8% revenues1

Artificial Intelligence, Advanced Analytics & Business Intelligence

US Healthcare has a strong regulatory framework with high compliance requirements

ISO 9001:2000 ISO 27001 HIPAA NCQA SISA PCI DSS SOC1 SOC2 URAC
5
Note: DME: Durable Medical Equipment. 1. For H1 FY25.
…Offering domain-led and digitally-enabled solutions
Healthcare Domain-Led Solutions Digitally-Enabled Solutions

1 2 3 4 5
Specialized High-Impact Functional Products & Process Optimization Integrated Tech-Led
Digital Services
End-to-End Program Services & Transformation Solutions (BPaaS)

✓ Building holistic, end-to-end in- ✓ Providing end-to-end workflow ✓ Leveraging best-of-breed tools to ✓ Utilizing data, analytics and AI ✓ Working with partners to
house programs and service solutions: provide operational value- add to services capabilities to deliver deliver integrated, tech+
platforms: clients: increased efficiencies: service offerings:
 Provider data management*
 Utilization Management  RPA Intelligent Content  Contact center as-a-service
Objectives


 Credentialing*
 Aging-in-place*  Process Mining Processing (ICP)*  Claims BPaaS
 LPI*
 Payment integrity*  Intelligent Interaction  Digital Intake
 Concierge services Analytics Platform (IIAP)*
 RCM as-a-service
 Patient self-pay  Business intelligence
 Speech Analytics*

✓ Providing care management ✓ Transformed provider data ✓ Delivered process optimization ✓ Use AI-based solutions to ✓ Deliver a digital document
services to LTC insurance management operation at a across multiple functions for a optimize inbound document management solutions for a
policy holders at a National mid-sized Blues Plan National payer management top 5 National payer
LTC carrier
Case Studies

✓ Created an intelligent workflow ✓ Built a smart and interactive ✓ Deliver RCM services for top 5
✓ Perform payment integrity for a Top-10 Health Plan to reduce speech analytics solution for National health system
audits for case completion, their late payment interest member and provider contact
correctness and clinical / center for a leading Blue Plan
financial findings

Deep Domain Expertise, Process Re-engineering and Transformation

Note: LPI: Late Payment Interest, RPA: Robotic Process Automation, BPaaS: Business Process-as-a-Service, TAT: Turn Around Time, TPA: Third Party administrator, RCM: Revenue Cycle Management, LTC: Long Term Care.
* In-house / Home-grown Technology. 6
Multiple GenAI Case studies across the enterprise

BirchAI’s proprietary technology uses Healthcare specific models from Speech-To-Text to LLMs

• Pre-Agent (Automate): Routine calls

resolved without human agent involvement • G&A Optimization: Identifies appeals
automatically to help resolve faster
• On Call: Keep agents on task, recommends
Next Best Actions and reduceAHT ENHANCE OPTIMIZE • Letter Generation for appeals, EOB and EOR

• After Call (Wrap time): Automate ENGAGEMENT BACK OFFICE • Optimize Knowledge Retrieval & Searching:
documentation and classification Helps agents resolve customer queries faster
Front Office Claims, PI, RCM •
• Audit & Analysis: Identify customer trends Fraud, Waste & Abuse Identification: Helps save
real-time, improve agent performance cost for clients

• Training optimization: Creating

• Clinical Summary and Documentation:
Summarises medical records to help nurses
relevant training content and OPERATIONAL in faster resolution
digitization of training delivery
PROFICIENCY CLINICIAN
• Improving speed to proficiency of EXCELLENCE • Coding Audits: Helps coders audit
efficiently and suggests alternate codes
agents Technology / where applicable
Shared Services UM, PI
• Adherence to Clinical Guideline: Aids
compliance

SagilityAI team will leverage BirchAI’s expertise to drive client transformation use cases

Note: AHT: Average Handle Time, PI: Payment Integrity, RCM: Revenue Cycle Management, EOB: Explanation Of Benefits, EOR: Explanation Of Review, UM: Utilization Management, G&A: Grievance and Appeals.

7
Focused growth strategy anchored on deepening existing relationships, winning new
clients, expanding tech capabilities and acquisitions

Identify suitable targets, and

effectively evaluate and execute
potential opportunities
Using analytics and tools for process
optimization and efficiency ⚫ Pursue acquisitions to expand
Establish new client relationships portfolio of services in Payer and
⚫ Cognitive computing
across categories Provider segments and other
̶ Artificial Intelligence (AI)
Strengthen relationships with existing adjacent segments
⚫ Payers: Continued focus on other ̶ Machine Learning (ML)
clients, expand offerings and increase ̶ Generative AI (GenAI)
large national & blue plans as well as ⚫ Add to the technology solutions
share of wallets
other regional plans ⚫ Cloud computing portfolio
⚫ Aim to leverage opportunities to up-
⚫ Providers: Expand RCM services to ⚫ Create capabilities across payment
sell and cross-sell by introducing
hospitals, health systems and other integrity, clinical management and
clients to the entire spectrum of
adjacent markets utilization management
solutions

⚫ Actively invest in capabilities to

expand service lines across clients

Strategic
Enhance Acquisitions and
Technology Tools Collaborations
New Clients
Existing Clients & Platforms
Addition
Growth

Clients Services Strategic Acquisitions and Collaborations 8

Key Highlights
Q2 FY25 Highlights H1 FY25 Highlights

► Revenue in Q2 at ₹13,250 million, grew by ₹2,309 million Y-o-Y ► Revenue in H1 at ₹ 25,484 million grew by ₹3,382 million Y-o-Y
(corresponding to 21.1% growth Y-o-Y ) (corresponding to 15.3% growth Y-o-Y )

► Adjusted EBITDA at ₹3,378 million, grew by ₹615 million Y-o-Y ► Adjusted EBITDA at ₹6,538 million, grew by ₹741 million Y-o-Y
(corresponding to 22.2% growth Y-o-Y ) (corresponding to 12.8% growth Y-o-Y )

► Adjusted PAT at ₹1,636 million, grew by ₹ 383 million Y-o-Y ► Adjusted PAT at ₹3083 million, grew by ₹405 million Y-o-Y
(corresponding to 30.5% growth Y-o-Y ) (corresponding to 15.1% growth Y-o-Y )

Key Business Highlights

► Robust expansion among existing clients driven by deep client relationships demonstrated by Client NPS of 53

► Strategic focus on small and mid-market segment payers and in widening presence with provider clients.

► Expansion in tech use-cases with multiple GenAI initiatives gathering momentum and pilots/ deployments underway; significant
enhancement in Automation and Analytics footprint.

► M&A continues to be a core pillar of our future growth.

► Strong performance driven by operational efficiencies

► People: Global headcount stands at 38,380 as of September 2024.

► 2,522 employees added during Q2 FY25 (7% Q-o-Q growth in headcount).

► Attrition low at 25.8%*

9
* Voluntary attrition considering employees who were employees for more than 90 days (%) on an annualized basis
 KPIs

KPI Q2 FY25 Q1 FY25 Q2 FY24 Y-o-Y % H1'25 H1'24 Y-o-Y %

Revenue from Operation (in INR Million) 13,250 12,233 10,941 21.1% 25,484 22,102 15.3%

Revenue by Vertical split

By Payer (in INR Million) 11,824 10,901 9,788 20.8% 22,725 19,773 14.9%
By Provider (in INR Million) 1,426 1,332 1,153 23.7% 2,758 2,329 18.4%

Growth in revenue from Operation (%) 21.1% 9.6% 15.3%

Adjusted EBITDA (in INR Million) 3,378 3.160 2,763 22.2% 6,538 5,797 12.8%
Adjusted EBITDA % 25.5% 25.8% 25.3% 25.7% 26.2%
Adjusted PAT (in INR Million) 1,636 1,447 1,254 30.5% 3,083 2,678 15.1%
Adjusted PAT % 12.3% 11.8% 11.5% 12.1% 12.1%

Total Number of Employees 38,380 35,858 36,525 5.1% 38,380 36,525 5.1%
Voluntary attrition rate* (%) 25.8% 27.3% 26.1% 26.2% 26.7%

10
*considering employees who were employees for more than 90 days (%) on an annualized basis
Financial Highlights
Highlights

Strong Q2 and H1 FY25 Performance

Q2 FY25 Financial Highlights H1 FY25 Financial Highlights

► Q2 FY25 revenue stood at ₹13,250 Million ($157.9 M) ► H1 FY25 revenue stood at ₹25,484 Million ($304.5 M)
► 21.1% growth Y-o-Y (19.8% at constant currency ) ► 15.3% growth Y-o-Y (13.8% at constant currency )
► 8.3% growth Q-o-Q (7.7% at constant currency)

► Adjusted EBITDA at ₹ 3,378 Million ($40.3 M) ► Adjusted EBITDA at ₹ 6,538 Million ($78.1 M)
► Adjusted EBITDA Margin : 25.5% ► Adjusted EBITDA Margin : 25.7%
► 22.2% growth Y-o-Y; 6.9% growth Q-o-Q ► 12.8% growth Y-o-Y

► Adjusted PAT at ₹1,636 Million ($19.5 M) ► Adjusted PAT at ₹3,083 Million ($36.8 M)
► Adjusted PAT Margin: 12.3% ► Adjusted PAT Margin : 12.1 %
► 30.5% growth Y-o-Y; 13.1% growth Q-o-Q ► 15.1% growth Y-o-Y

► OCF ₹2,391 Million ($ 28.4 M) ► OCF ₹6,089 Million ($72.8 M)

► 75.5% of EBITDA ► 113.8% of EBITDA

12
Financial performance snapshot – Q2 FY25

Revenue Y-o-Y Q-o-Q Adjusted EBITDA Y-o-Y Q-o-Q Adjusted PAT Y-o-Y Q-o-Q
(INR Million) 21.1% 8.3% (INR Million) 22.2% 6.9% (INR Million) 30.5% 13.1%

₹13,250 ₹3,378 ₹1,636

₹12,233 ₹3,160
₹10,941 ₹2,763 ₹1,447
₹1,254

Q2'24 Q1'25 Q2'25 Q2'24 Q1'25 Q2'25 Q2'24 Q1'25 Q2'25

Y-o-Y Q-o-Q Adjusted EBITDA Y-o-Y Q-o-Q Adjusted PAT Y-o-Y Q-o-Q
Revenue ($M) ($M)
19.8% 7.7% 20.9% 6.3% ($M) 29.1% 12.5%
$157.9
$37.9 $40.3 $19.5
$146.6
$33.3 $17.3
$15.1
$131.9

Q2'24 Q1'25 Q2'25 Q2'24 Q1'25 Q2'25 Q2'24 Q1'25 Q2'25

13
Financial performance snapshot – Long Term

Revenue FY24 Y-o-Y H1’25 Y-o-Y Adjusted EBITDA FY24 Y-o-Y H1’25 Y-o-Y Adjusted PAT FY24 Y-o-Y H1’25 Y-o-Y
(INR Million) 12.7% 15.3% (INR Million) 12.1% 12.8% (INR Million) 29.4% 15.1%

₹47,536
₹42,184
₹11,715 ₹5,896
₹10,449
₹4,556
₹25,484
₹22,102 ₹6,538
₹5,797 ₹2,678 ₹3,083

FY23 FY24 H1 FY24 H1 FY25 FY23 FY24 H1 FY24 H1 FY25 FY23 FY24 H1 FY24 H1 FY25

FY24 Y-o-Y H1’25 Y-o-Y Adjusted EBITDA FY24 Y-o-Y H1’25 Y-o-Y Adjusted PAT FY24 Y-o-Y H1’25 Y-o-Y
Revenue ($M)
10.5% 13.8% ($M) 10.0% 11.3% ($M) 26.9% 13.6%

$141.2 $71.1
$128.4
$572.9 $56.0
$518.2
$70.2 $78.1
$36.8
$267.6 $304.5 $32.4

FY23 FY24 H1 FY24 H1 FY25 FY23 FY24 H1 FY24 H1 FY25 FY23 FY24 H1 FY24 H1 FY25

14
Financial Indicators
Adjusted EPS (in INR) Adjusted ROCE
1.38 1.43 47.0%

1.06 45.1%

41.6%

FY23 FY24 TTM Sep24 FY23 FY24 TTM Sep24

Net Debt
Cash Conversion (%)
113.8% ₹22,863 ₹21,678
101.1%
82.0% 87.2% 2.19x
68.2% 70.8% 1.85x
₹9,736

0.78x

FY23 FY24 H1 FY 25 Mar-23 Mar-24 TTM Sep24

OCF FCF Net Debt (INR million) Net Debt to Adjusted EBITDA

Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares
Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles less current liabilities)
Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest
15
Q2 & H1 FY25 Consolidated Financials
Amt in INR M

Particulars Q2'25 Q1'25 Q2'24 QoQ% YoY% H1'25 H1'24 YoY%

Revenue from Operation 13,250 12,233 10,941 8.3% 21.1% 25,484 22,102 15.3%

Other Income 153 244 291 189 405

Employee benefits expense 8,124 8,504 6,805 16,628 13,399

Other expenses 2,115 1,790 1,795 3,696 3,725

Reported EBITDA 3,165 2,184 2,632 44.9% 20.3% 5,349 5,383 -0.6%

Adjusted EBITDA 3,378 3,160 2,763 6.9% 22.2% 6,538 5,797 12.8%

Adjusted EBITDA % 25.5% 25.8% 25.3% 25.7% 26.2%

Finance costs 297 374 483 671 954

Depreciation and amortisation expenses 1,264 1,100 1,715 2,363 3,376

Profit Before Tax 1,604 710 434 125.9% 269.8% 2,314 1,053 119.8%

Tax Expenses 431 487 84 918 278

Reported Profit After Tax 1,173 223 350 426.3% 235.6% 1,396 775 80.3%

Adjusted PAT 1,636 1,447 1,254 13.1% 30.5% 3,083 2,678 15.1%

Adjusted PAT % 12.3% 11.8% 11.5% 12.1% 12.1%

Adjusted EPS (Basic and Diluted) (Rs) 0.35 0.33 0.29 6.9% 19.5% 0.64 0.62 2.3%

* Financials for Q2FY25, H1’25 and H1’24 are unaudited. Financials for Q1’25 are audited
16
Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q2 FY25 Adj EBITDA Bridge: H1 FY25
INR Million INR Million

Reported Adjusted Reported Adj A Adj B Adjusted

Adj A Adj B
EBITDA EBITDA EBITDA EBITDA

Adj PAT Bridge: Q2 FY25 Adj PAT Bridge: H1 FY25

INR Million INR Million

Reported Adj A Adj B Adj C Adjusted Reported Adj A Adj B Adj C Adjusted
PAT PAT PAT PAT

Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax
Adj B - Share based payment awards and for PAT it is adjusted for tax
17
Adj C - Intangible assets Amortization is amortization of intangible assets acquired pursuant to business combinations and for PAT it is adjusted of tax
Go Forward Positions

Amt in INR Million

Particulars FY'25 FY'26 FY'27 FY'28 FY'29

Closing Debt position 8,020 5,670 - - -

Debt Repayment 2,490 2,350 5,670

Interest Payment 746 535 285

Share based payment awards 1,088 215 131 71 34

Earnouts Cost - DCI / Birch 479 343 - - -

Intangibles Amortisation 1,387 1,396 1,396 1,396 1,396

* Numbers are based on the current visibility of management and are subject to change. Factors such as new loans, acquisitions, foreign exchange rate or changes in our share-based payment
award plan could impact the final figures

18
Balance Sheet
Amt in INR Million

Particulars Sep'24 Mar'24

Property, plant and equipment 3,869 3,832
Capital-work-in-progress - 57
Right-of-use assets 5,244 5,665
Goodwill 57,088 57,096
Other intangible assets 19,365 20,078
Trade receivables 10,578 11,813
Cash and cash equivalents 5,068 3,441
Deferred tax assets (net) 1,315 1,354
Other Assets 3,776 3,305
Total assets 106,303 106,642
Equity 78,159 64,431
Borrowings 9,441 19,335
Lease liabilities 5,540 5,982
Trade payables 2,706 2,593
Other financial liabilities 2,643 6,587
Deferred tax liabilities (net) 4,605 4,710
Other Liabilities 3,209 3,004
Total Liabilities 106,303 106,642
* Financials for Sept’24 are unaudited. Financials for Mar’24 are Audited
19
Consolidated Cash Flow – H1 FY25
Amt in INR Million
Particulars H1'25 FY'24
Profit before tax for the period/ year 2,314 2,417
Adjustment for Non-Operating and Non-Cash 4,033 8,693
Adjustment for working capital 522 (114)
Income taxes paid (net of refunds) (781) (1,263)
Net cash flows generated from operating activities (A) – OCF 6,089 9,733
Acquisition of property, plant and equipment and other intangible assets (682) (1,827)
Free Cash Flows (FCF) 5,407 7,905
Payment for business combination, net of cash acquired (3,756) (3,010)
Others 82 147
Net cash flows (used in) investing activities (B) (4,356) (4,691)
Proceeds from issue of shares by subsidiaries in a related party transaction 3,708
Share issue expense paid (5) (72)
Repayment of borrowings (2,427) (4,281)
Repayment of lease liabilities (782) (1,265)
Interest on repayment of lease liabilities (130) (412)
Interest paid on borrowings (473) (1,483)
Net cash flows (used in) financing activities (C) (109) (7,513)
Net increase/ (decrease) in cash and cash equivalents (A+B+C) 1,624 (2,471)
Cash and cash equivalents at the beginning of the year/period 3,441 5,853
Effect of movement in exchange rates on cash and cash equivalents 3 60
Cash and cash equivalents at the end of the year/ period 5,068 3,441
Net cash flows generated from operating activities % (OCF on EBITDA) 113.8% 87.2%
Free Cash flow % (FCF on EBITDA) 101.1% 70.8%

• Financials for Sept’24 are unaudited. Financials for Mar’24 are Audited
• Others in investing activities include Proceeds from sale of property, plant and equipment and other intangible assets and Proceeds from
maturity of derivative assets/liabilities, (net) and Interest received 20
Thank You